MARKET

VYNE

VYNE

Vyne Therapeutics Inc
NASDAQ
2.960
+0.130
+4.59%
After Hours: 2.850 -0.11 -3.72% 19:30 03/27 EDT
OPEN
2.850
PREV CLOSE
2.830
HIGH
3.080
LOW
2.800
VOLUME
288.45K
TURNOVER
0
52 WEEK HIGH
8.73
52 WEEK LOW
1.670
MARKET CAP
41.73M
P/E (TTM)
-1.0687
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VYNE last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at VYNE last week (0311-0315)?
Weekly Report · 03/18 11:15
Weekly Report: what happened at VYNE last week (0304-0308)?
Weekly Report · 03/11 11:12
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
NASDAQ · 03/08 17:00
Weekly Report: what happened at VYNE last week (0226-0301)?
Weekly Report · 03/04 11:14
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
Vyne Therapeutics Inc. Faces long-term business risks stemming from climate change. The company has disclosed a new risk in the Natural and Human Disruptions category. Wall Street has a Moderate Buy consensus rating on Vyne stock based on 2 Buys.
TipRanks · 03/03 06:01
Vyne Therapeutics files for $250M mixed shelf
Healthcare Vyne Therapeutics files for $250M mixed shelf to raise $250 million. SEC filing says company plans to offer and sell common stock, preferred stock, and warrants to raise the money. The company is a subsidiary of Vyne Pharmaceuticals Inc.
Seeking Alpha · 03/01 22:40
Catalyst Watch: Jobs report, Powell treks to Congress, Target earnings and major tech conference
Seeking Alpha · 03/01 20:00
More
About VYNE
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Webull offers Vyne Therapeutics Inc stock information, including NASDAQ: VYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYNE stock methods without spending real money on the virtual paper trading platform.